At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
A key highlight will be Brenntag’s qualified amino acids portfolio
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies
Subscribe To Our Newsletter & Stay Updated
